stockrowuniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024.
- Revenue
- +40.4%
- EPS
- +36.5%
- Free cash flow
- +27.7%
- Total debt
- −2.96%
Quarter to September 2026, against a year earlier
Follow QURE
Alert me
uniQure N.V. (QURE) EV/Sales
As of 6 November 2026, uniQure N.V. (QURE) trades at a EV/Sales of 44.7×. Over the past ten years it has ranged from −17.6× (March 2024) to 432× (June 2020); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 50.4× | 148.00% |
| FY2024 | 20.3× | — |
| FY2023 | −11.2× | — |
| FY2022 | 7.3× | 656.41% |
| FY2021 | 1.0× | (97.42%) |
| FY2020 | 37.5× | (89.23%) |
| FY2019 | 348× | 369.57% |
| FY2018 | 74.1× | 139.51% |
| FY2017 | 30.9× | 2,137.03% |
| FY2016 | 1.4× | (91.07%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 53.5× | (56.55%) |
| Jun 2026 | 123× | 347.85% |
| Mar 2026 | 27.5× | (45.45%) |
| Dec 2025 | 50.4× | (71.46%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TYRA Tyra Biosciences, Inc. compare | n/m |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.6× |
| NUVB Nuvation Bio Inc. compare | 5.4× |
| PGEN Precigen, Inc. compare | 10.5× |
| OCUL Ocular Therapeutix, Inc. compare | 18.5× |
| QURE uniQure N.V. | 44.7× |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 5,356× |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)